MicroRNA-206 has a bright application prospect in the diagnosis of cases with oral cancer.
MiR-206
diagnosis
oral cancer
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
02
03
2021
received:
30
11
2020
accepted:
22
03
2021
pubmed:
22
8
2021
medline:
15
2
2022
entrez:
21
8
2021
Statut:
ppublish
Résumé
Previous studies have shown that microRNA-206 (miR-206) exhibits anti-tumour properties in various tumours. Nevertheless, diagnostic significance of miR-206 in oral cancer is still poorly known. Our research was carried out to explore the performance of miR-206 in the diagnosis of oral cancer. Quantitative real-time polymerase chain reaction (qRT-PCR) method was adopted to measure the level of miR-206 in serum specimens from oral cancer cases and control individuals. Chi-square test was performed to analyse the correlation between miR-206 level and clinicopathological parameters of the cases. Receiver operating characteristic (ROC) curve was constituted to assess diagnostic accuracy of miR-206 in oral cancer. Serum miR-206 level in oral cancer patients was significantly lower than that in control individuals (P < .001). miR-206 expression was obviously related to T classification (P = .033), TNM stage (P = .008) and lymph node metastasis (P = .028). The area under the curve (AUC) of the ROC curve was 0.846 (95% CI = 0.797-0.896, P < .001) with a specificity of 72.7% and a sensitivity of 81.2%. It revealed that miR-206 might be a non-invasive indicator in differentiating oral cancer cases from control individuals. Down-regulation of miR-206 is related to the development of oral cancer. Serum miR-206 might be an effective indicator for early detection of oral cancer.
Identifiants
pubmed: 34418889
doi: 10.1111/jcmm.16598
pmc: PMC8419190
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN206 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8169-8173Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Eur J Gastroenterol Hepatol. 2013 Aug;25(8):953-7
pubmed: 23751352
PLoS One. 2014 Sep 19;9(9):e107986
pubmed: 25238238
J Cancer Res Clin Oncol. 2016 Mar;142(3):581-92
pubmed: 26515696
Oncotarget. 2016 Apr 5;7(14):18247-61
pubmed: 26919096
Onco Targets Ther. 2014 Sep 11;7:1583-91
pubmed: 25246801
Curr Pharm Des. 2016;22(34):5257-5269
pubmed: 26935703
J Cell Mol Med. 2021 Sep;25(17):8169-8173
pubmed: 34418889
Oncotarget. 2016 Apr 26;7(17):24537-48
pubmed: 27014911
Biochem Biophys Res Commun. 2016 Aug 26;477(3):461-6
pubmed: 27318091
Asian Pac J Cancer Prev. 2013;14(6):3751-5
pubmed: 23886177
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4194-203
pubmed: 25120799
Eur J Gynaecol Oncol. 2015;36(6):716-21
pubmed: 26775359
PLoS One. 2016 Jul 21;11(7):e0159693
pubmed: 27441818
Oncotarget. 2015 Sep 22;6(28):25533-74
pubmed: 26325180
Clin Biochem. 2015 Feb;48(3):115-21
pubmed: 25485932
J Clin Diagn Res. 2016 Feb;10(2):ZC34-7
pubmed: 27042582
Oncol Lett. 2016 Aug;12(2):1171-1177
pubmed: 27446414
Cancer Biomark. 2015;15(4):391-6
pubmed: 26406866
Cancer Lett. 2016 Apr 28;374(1):107-116
pubmed: 26808577
Int J Clin Exp Med. 2015 Jun 15;8(6):9107-13
pubmed: 26309565
Int J Clin Exp Pathol. 2015 Mar 01;8(3):3097-103
pubmed: 26045823
Pathol Oncol Res. 2014 Apr;20(2):343-8
pubmed: 24390803
Int J Mol Sci. 2016 Jun 24;17(7):
pubmed: 27347940
Int J Clin Exp Med. 2015 Jun 15;8(6):9239-47
pubmed: 26309581
Oncol Rep. 2016 Mar;35(3):1778-86
pubmed: 26718123
Eur Rev Med Pharmacol Sci. 2015;19(14):2697-702
pubmed: 26221902
Hepatogastroenterology. 2014 Jul-Aug;61(133):1302-7
pubmed: 25436301
Saudi Med J. 2016 Jun;37(6):607-12
pubmed: 27279505
Int J Biol Sci. 2015 Feb 05;11(3):345-52
pubmed: 25678853